GET DAILY SIGNALSAlto Neuroscience (ANRO): Analyst Targets Point to +43% Upside to $40
Key Takeaways
- The central target of $40 is the arithmetic mean of roughly 11 verified analyst price targets (approximately $38.67), rounded to a clean level.
- Individual targets range from about $26 to $60, a wide spread that reflects the binary, catalyst-driven nature of a clinical-stage biotech.
- With shares recently trading near $28, reaching $40 implies an upside of roughly 43% — a substantial move.
- The strongest supports are a roughly $320 million cash position expected to fund operations into 2030 and a late-stage lead program (ALTO-207) with key readouts in 2027.
- The biggest risks are trial failure or delay, a lack of near-term revenue, and potential valuation compression if 2027 data disappoint.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- Investors seeking data-driven trade ideas can also explore Trending AI Robots.
Analyst Price Targets and Consensus View
Roughly 11 current analyst price targets were reviewed, spanning from about $26 on the cautious end to $60 on the bullish end. The arithmetic mean works out to approximately $38.67, which is rounded to a $40 central target for this analysis. It is important to note that this is a calculated average of individual targets, not an official published consensus.
The spread tells the story. H.C. Wainwright's Patrick Trucchio raised his target to $60 from $55 in October 2026, arguing that independent pramipexole data support ALTO-207's mechanism and that the three-trial PACE program could broaden the drug's indication. Bank of America and Jefferies each moved targets into the $40 area in August 2026, while BTIG lifted its target to $37. At the other end, Wedbush holds a Neutral rating with a target near $26, reflecting a more conservative view of the clinical and execution risk. The gap between the top and bottom targets underscores that analysts broadly agree on the opportunity but disagree sharply on how much of it is already priced in. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares have recently traded near $28, within a 52-week range of roughly $10.80 to $37.48. Reaching the $40 central target would therefore require a gain of about 43%, which is a substantial move for a pre-revenue company whose value is tied to data releases rather than quarterly results.
The path toward that level is event-driven rather than earnings-driven. Alto Neuroscience, Inc. (NYSE: ANRO) reported a third-quarter 2026 net loss of $25.1 million, or $0.54 per share, and closed the quarter with roughly $319.8 million in cash, cash equivalents, and restricted cash — funding the company expects to carry it through 2030. The lead asset, ALTO-207 (a modified-release combination of pramipexole and ondansetron) for treatment-resistant depression, has topline data from its PACE-1 Phase 2b trial expected in the second half of 2027, with Phase 3 studies planned around it. Positive readouts on ALTO-300 (major depressive disorder, first half of 2027) and ALTO-100 (bipolar depression, mid-2027) could also re-rate the shares.
What Could Support a Move Toward the Target
- A fortified balance sheet: the July 2026 financing raised roughly $100 million in gross proceeds, extending the cash runway and reducing near-term dilution risk.
- A catalyst-rich 2027: three pivotal data readouts and potential Phase 3 initiations give analysts concrete events to underpin higher targets.
- Mechanistic validation: independent pramipexole data cited by bullish analysts reinforce confidence in ALTO-207's approach to treatment-resistant depression.
- A differentiated precision-psychiatry strategy that aims to match patients to drugs using biomarkers, a narrative that has attracted continued Buy ratings.
What Could Prevent the Target From Being Reached
- Clinical binary risk: a failed or delayed ALTO-207 trial would likely remove much of the valuation support behind current targets.
- No product revenue: the company's losses are widening (R&D spending rose to $18.2 million in Q3 2026), and funding needs could return if timelines slip.
- Valuation sensitivity: at a market capitalization near $1 billion with no sales, the stock is vulnerable to sentiment shifts and sector rotation away from speculative biotech.
- Wide target dispersion: the $26-to-$60 range shows that even bullish analysts disagree on how much upside is realistic, and cautious views imply meaningful downside from current levels.
Technical Levels and Market Structure
The shares remain well below the 52-week high near $37.48, which now functions as a meaningful resistance zone on any advance toward $40. The psychologically important $40 level sits just above that prior high, so a move to the central target would likely require breaking through both. On the downside, the 52-week low near $10.80 is distant, but the stock's history of sharp, news-driven swings means that support is defined more by financing milestones and data catalysts than by stable technical floors.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state a uniform timeframe. Investors should watch the late-2026/early-2027 FDA interaction and Phase 1 formulation data for ALTO-207, the initiation of the PACE-2 Phase 3 trial in early 2027, and the ALTO-300 and ALTO-100 Phase 2b readouts later in 2027. Quarterly cash burn, analyst revisions around each data event, and any regulatory feedback will be the key drivers of the stock's trajectory.
Using AI Daily Buy/Sell Signals in Practice
In my research process for names like this, I sometimes review AI Daily Buy/Sell Signals from Tickeron. These tools apply artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical patterns. For a catalyst-driven stock where price action can move quickly around trial news, the signals offer a way to track trends and surface potential entry or exit points alongside fundamental analysis.
Final Assessment
The question of whether Alto Neuroscience, Inc. (NYSE: ANRO) can reach $40 rests less on financial performance than on clinical execution. The central target is a calculated average of analyst price targets spanning roughly $26 to $60, and the roughly 43% required move is substantial. A strengthened cash position and a busy 2027 catalyst calendar provide the foundation for bullish targets, while the absence of revenue and the binary nature of trial outcomes are the principal obstacles. With no way to know in advance how the data will read, investors should treat the target as a reflection of analyst expectations rather than a forecast, and focus on the upcoming regulatory interactions and trial readouts that will ultimately determine the stock's path.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ANRO turns positive, indicating new upward trend
ANRO saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator turned positive. In 44 of the 47 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ANRO just turned positive on October 20, 2026. Looking at past instances where ANRO's MACD turned positive, the stock continued to rise in 13 of 17 cases over the following month. The odds of a continued upward trend are 76%.
ANRO moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +13.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANRO advanced for three days, in 151 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ANRO broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ANRO entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.503) is normal, around the industry mean (3.498). P/E Ratio (-10.845) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ANRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement